590 nm 660 nm 850 nm

From Photon to Photoreceptor

The Science and Clinical Application of Light Therapy in Eye Care

James Deom, OD, MPH, FAAO, FSLS · Hazleton Eye Specialists

September 22, 2026 · COPE Course ID: [pending] · 2.0 CE Hours

REQUIRED DISCLOSURES

Financial Disclosures

- Consultant / Speakers Bureau: [None]
- Research Support / Investigator: None]
- Equity / Ownership Interest: [None]
- Royalties / Intellectual Property: [None]

"All relevant relationships have been mitigated."

- This course is COPE-accredited and free of commercial bias.
- Off-label / investigational uses — photobiomodulation for diabetic macular edema, retinitis pigmentosa, glaucoma, and myopia control — will be explicitly identified as such when discussed.
- Trade names are used only where required for clinical clarity; competing technologies are presented where they exist.

Dedicated to Advancement and Clinical Excellence

- 5 Locations
- 10 Doctors
- Continue to innovate and bring new treatments



HAZLETON EYE SPECIALISTS

- 281 Airport Road
  Hazle Township, PA 18202
  Phone: 570-453-2020




STROUDSBURG EYE SPECIALISTS


BANGOR EYE SPECIALISTS

385 Bangor Junction Rd.
Bangor, PA 18013
Phone: 610-588-0129

NANTICOKE EYE SPECIALISTS

- Conveniently located in the Wyoming Valley
- Specializing in Brain Injury and Vision Development
- Comprehensive Eye Care
- Retinal Specialty Care – injections, lasers

245 S. Prospect St.
Nanticoke, PA 18634
Phone: 570-735-6000
Fax: 570-735-5300

7 / 100

POTTSVILLE EYE SPECIALISTS

- 541 West Bacon Street
  Pottsville, PA 17901
  Phone: 570-628-3937

8 / 100

BRIGHT EYES & FACE
MEDSPA
POCONOS, PA

2 Locations, 1 Medical Director 2 Pas, 3 CRNPs, 1 RN, 2 Front Desk

9 / 100

Bedford through the years

10 / 100

COURSE OBJECTIVES

Learning Objectives

1 Describe the mechanisms
Chromophore absorption by cytochrome c oxidase, mitochondrial ATP production, ROS and inflammatory modulation, and wavelength-dependent penetration.

2 Differentiate the modalities
LLLT, IPL, and multiwavelength PBM — mechanism, dosimetry, regulatory status, and appropriate indications.

3 Apply the AMD evidence
Use LIGHTSITE I–III and supporting RCTs to select candidates, counsel on expected outcomes, and implement the treatment protocol.

4 Evaluate safety & limits
Safety profile, contraindications, Cochrane and AAO assessments, phototoxicity reports, and gaps in standardization.

11 / 100

AGENDA

Roadmap: Four Parts, 120 Minutes

I	Physics & Biology of Therapeutic Light	25 min
II	History of Light in Medicine	20 min
III	Anterior Segment: Dry Eye & MGD	35 min
IV	Posterior Segment: PBM for Dry AMD	40 min

12 / 100

PART I · PHYSICS & BIOLOGY

The Electromagnetic Spectrum



Photobiomodulation band: ~600–1100 nm (red + near-infrared)

- Visible window: 400–700 nm; the "optical window" of useful tissue penetration spans roughly 600–1200 nm.
- Infrared subdivides into IR-A (760–1400 nm), IR-B, and IR-C — only IR-A is therapeutically relevant here.
- Every therapy in this lecture — IPL, LLLT, multiwavelength PBM — lives on this one axis. Where a device sits determines what it can reach and what it can do.

PART I · PHYSICS & BIOLOGY

Photon Energy and the First Law of Photobiology

First law of photobiology: a photon must be absorbed by a molecule in the tissue to produce any biologic effect.

$$E = hc / \lambda$$

Planck relation: photon energy is inversely proportional to wavelength

- Shorter wavelength → higher photon energy → greater phototoxic potential (UV at the extreme).
- Longer wavelength → lower photon energy → deeper tissue penetration (near-infrared at the extreme).
- Therapeutic light design is the art of trading energy against depth to reach the intended chromophore safely.

KEY POINT No absorption, no effect — every claim about a light therapy must start by naming the absorbing molecule.

PART I · PHYSICS & BIOLOGY

The Vocabulary of Dosimetry

Parameter	Units	What it determines
Wavelength	nm	Which chromophore absorbs; how deep the light travels
Irradiance (power density)	mW/cm²	Rate of energy delivery
Fluence (energy density)	J/cm²	Total dose delivered
Pulse structure / duty cycle	—	Peak vs. average power; thermal relaxation between pulses
Total irradiation time	s / min	Cumulative exposure; separates PBM from photothermal modes
Beam properties	—	Coherent (laser) vs. non-coherent (LED); collimated vs. divergent

KEY POINT Effective therapy is parameter-dependent — fluence, duration, and output power — not merely wavelength-dependent.

PART I · PHYSICS & BIOLOGY

Why "Red Light" Is Not One Therapy

Same wavelength, different irradiance

A 660 nm panel at 5 mW/cm² and a 660 nm laser at 500 mW/cm² are different interventions.

Same fluence, different delivery

10 J/cm² continuous vs. pulsed at low duty cycle produce different tissue responses.

Same device, different protocol

Session count, spacing, and total irradiation time change outcomes independently of the source.

Central teaching point: never compare devices on wavelength alone. Parameter variation is a recognized source of uncertainty in therapeutic efficacy and a barrier to standardization of treatment protocols.

PART I · PHYSICS & BIOLOGY

Four Modes of Light–Tissue Interaction

Photochemical

Photon drives a chemical reaction

PDT · bilirubin photoisomerization · vitamin D synthesis

Photothermal

Absorbed energy becomes heat

Conventional retinal laser · micropulse · IPL lid heating

Photomechanical

Nanosecond pulses create mechanical disruption

YAG capsulotomy · selective retina therapy (SRT) · 2RT

Photobiomodulation

Sub-thermal metabolic signaling

LLLT · multiwavelength retinal PBM — the subject of this course

PART I · PHYSICS & BIOLOGY

The RELITE Nomenclature Framework



- Categorizes regenerative retinal laser and light therapies by pulse duration and total irradiation time.
- Explicitly separates PBM from photothermal and photomicrodisruptive modalities — a trial-reporting standard the field currently lacks.

PART I · PHYSICS & BIOLOGY

Cytochrome c Oxidase: The Primary Chromophore

- Complex IV of the mitochondrial electron transport chain — the terminal enzyme that hands electrons to oxygen.
- Contains heme a / a_3 and Cu_A / Cu_B redox centers — these metal centers are the light absorbers.
- Absorption peaks in the red and blue regions, extending into the near-infrared up to approximately 900 nm.
- Highly expressed in metabolically demanding tissue — photoreceptors and RPE are among the most mitochondria-dense cells in the body.
- The action spectrum for CCO activity and ATP content parallels CCO's NIR absorption spectrum, with activity increased at 660 and 850 nm.



The chromophore's home: Complex IV sits on the inner mitochondrial membrane.

PART I · PHYSICS & BIOLOGY

The Nitric Oxide Photodissociation Hypothesis



- Nitric oxide competes with oxygen at CCO's active sites; photodissociation of NO restores oxygen binding and respiration.
- The red-light (CCO) and near-infrared (ion channel) pathways converge through ROS and cAMP onto gene-level effects.
- This is a hypothesis with strong but incomplete support — mechanism uncertainty is one reason PBM acceptance lagged for decades.

PART I · PHYSICS & BIOLOGY

Secondary Chromophores and Ion Channels

Photoacceptor	Activating wavelengths	Downstream signal
TRP-superfamily channels (incl. TRPV1)	Green, red, near-infrared	Cation influx — calcium entry into the cytosol
Opsins (non-visual)	Blue–green	G-protein signaling cascades
Flavins / flavoproteins	Blue	Redox signaling, ROS generation
Cytochrome c oxidase (primary)	Red, near-infrared (to ~900 nm)	ATP, ΔΨm, NO release

KEY POINT Multiple chromophores with different absorption spectra are the biologic rationale for multiwavelength devices.

PART I · PHYSICS & BIOLOGY

Downstream Signaling: From Photon to Gene Expression

Second messengers

- Reactive oxygen species (signaling-level)
- Cyclic AMP
- Nitric oxide
- Calcium

→

Transcription pathways

- PI3K / Akt
- MAPK
- NF-κB modulation
- Transcription factor activation (e.g., via redox state)

→

Gene programs ↑

- Protein synthesis
- Cell migration & proliferation
- Anti-inflammatory signaling
- Anti-apoptotic proteins
- Antioxidant enzymes

KEY POINT Stem and progenitor cells appear particularly susceptible to photobiomodulation — relevant to regenerative claims.

PART I · PHYSICS & BIOLOGY

The Biphasic Dose Response (Arndt–Schulz Curve)

- PBM exhibits wavelength- and dose-dependent bidirectional regulation.
- Under-dosing → no measurable effect.
- Over-dosing → response flattens, then becomes inhibitory.

"More" is not "better" — the most practical single fact in this hour.

PART I · PHYSICS & BIOLOGY

The Espresso Model of Dosimetry

The roast you choose	→	**Wavelength (nm)** — selects the chromophore — what absorbs at all
How strong you brew	→	**Irradiance (mW/cm²)** — power density at the tissue
How long you drink	→	**Exposure time (s)** — duration per session
Total shots consumed	→	**Fluence (J/cm²)** — irradiance × time — the delivered dose
Sipping vs chugging	→	**Pulse structure** — same dose, different delivery, different biology
1 shot sharpens · 10 shots shut you down	→	**Biphasic dose response** — the Arndt–Schulz curve from the last slide

Same beverage, very different afternoon. Nobody orders "a coffee" at a specialty cafe — stop ordering "red light" from a device catalog. Parameters predict outcomes.

PART I · PHYSICS & BIOLOGY

Penetration Depth by Wavelength

- Red 620–700 nm and NIR 700–1440 nm are the therapeutic PBM bands.
- NIR reaches deepest — the choice for posterior segment targets.



PART I · PHYSICS & BIOLOGY

Part I Summary: Three Rules of Therapeutic Light

1. **Wavelength selects the chromophore**
   Which molecule absorbs — and therefore which tissue and which biology you engage.
2. **Dose determines direction**
   The biphasic curve: too little does nothing, too much inhibits.
3. **Parameters determine reproducibility**
   Irradiance, fluence, pulse structure, and schedule — the difference between a therapy and an anecdote.

PBM's promise as an adjunct: non-invasive, minimal tissue damage, favorable safety, low cost.

PART II · HISTORY OF LIGHT IN MEDICINE

Ancient Heliotherapy: Five Millennia of Sun as Medicine

~3000 BCE — Egyptian records link sun exposure and skin disease — the earliest known association, five millennia old.

~1500 BCE — Egyptian and Indian healers combine plant extracts or seeds with sunlight to treat "leucoderma" — psoralen-like photochemotherapy avant la lettre.

Antiquity — Greek and Roman solaria; heliotherapy as a formal element of care.

Plant extracts + sunlight, ~1500 BCE (AI-generated illustration)

PART II · HISTORY OF LIGHT IN MEDICINE

The 19th-Century Scientific Turn

1877

Downes & Blunt demonstrate that light exposure inhibits fungal growth and kills anthrax bacilli in test tubes — photobiology becomes an experimental science.

Enabling technologies

- Characterization of ultraviolet radiation
- The electric generator
- The electric lightbulb

KEY POINT These discoveries moved medicine from waiting for the sun to engineering the source — heliotherapy became phototherapy.

PART II · HISTORY OF LIGHT IN MEDICINE

Niels Ryberg Finsen (1860–1904): Founder of Modern Phototherapy

- Applied an electric carbon arc torch with quartz filters to treat lupus vulgaris — cutaneous Mycobacterium tuberculosis.
- Treated more than 800 patients at the Finsen Institute in Copenhagen.
- Awarded the 1903 Nobel Prize in Physiology or Medicine — the origin point of medical phototherapy as a discipline.
- Note the template he set: engineered source, filtered spectrum, defined target disease — the same anatomy as every modern device study.

Multi-arm carbon-arc phototherapy, early 1900s (AI-generated recreation)

PART II · HISTORY OF LIGHT IN MEDICINE

Sanatoria, Rickets, and the Road to Vitamin D

1921 — Sunlight published as the cure for rickets.

1925 — Hess & Weinstock: UV-irradiated food prevents rickets in rats — the path to vitamin D.

1900s–1950s — European and North American sanatoria deploy heliotherapy for tuberculosis; UV therapy and vitamin D remain in use until antibiotics supersede them.

Dermatologic Phototherapy Matures

- **1923** Goeckerman selects UVB with coal tar for psoriasis.
- **1932** AMA review lists 34 skin conditions for which UV radiation might be useful.
- **1947** Methoxypsoralen isolated.
- **1974** PUVA photochemotherapy — photodermatology expands rapidly.
- **1980s** Narrow-band UVB emerges from action-spectrum work in psoriasis.

Grzybowski A, et al. 2016 · Hönigsmann H. 2013 · Bouzari-Mendes R, et al. Photodermatol Photoimmunol Photomed. 2022;38(3):215-223 · Kenett & Scragg 2017.

Phototherapy Expands Beyond Dermatology

Neonatology
Blue-light phototherapy for hyperbilirubinemia — next two slides.

Psychiatry
Bright-light therapy for seasonal affective disorder.

Ophthalmology
From retinal photocoagulation to photobiomodulation — the rest of this course.

Grzybowski A, et al. Clin Dermatol. 2016;34(5):532-537.

Neonatal Jaundice: From Nursing Observation to Standard of Care

1950s
Rochford Hospital, England: Sister J. Ward observes jaundice fading on the sun-exposed skin of premature infants.

→

1958
Cremer, Perryman & Richards publish the influence of light on infant hyperbilirubinaemia in The Lancet.

→

1968
Lucey's randomized controlled trial establishes efficacy — phototherapy becomes standard of care.

Blue LED phototherapy with eye shields (AI-generated illustration)

KEY POINT Serendipity → case report → randomized trial: the same evidentiary arc photobiomodulation is traversing today.

Cremer RJ, et al. Lancet. 1958;1(7030):1094-1097 · Lucey J, et al. Pediatrics. 1968;41(6):1047-1054.

Blue Light as a Dosed Drug

- Sources evolved: fluorescent tubes → halogen spotlights → fiberoptic pads → narrow-band blue LEDs matched to the bilirubin photoisomerization peak (~458 nm).
- The prescription is a dose: irradiance, lamp distance, and exposed surface area — titrated like a drug.
- Devices should emit no UV and no infrared — spectral purity is a safety parameter, not a refinement.

The "dose" of phototherapy

- Spectral match to the chromophore
- Irradiance at the skin
- Distance from source
- Exposed surface area
- Duration of exposure

An exact template for how we will evaluate ocular devices.

Mester and the Accidental Discovery of Biostimulation

- Budapest, late 1960s: Endre Mester applies a low-power ruby laser to shaved mice expecting to test carcinogenicity.
- Instead: accelerated hair regrowth and faster wound healing — laser "biostimulation" is born, later renamed low-level laser therapy (LLLT).
- The finding was real but the field stalled: photobiomodulation has been known for almost 50 years yet did not gain widespread acceptance, largely because of persistent uncertainty about its mechanisms.
- Lesson for the audience: a therapy without a mechanism narrative struggles for legitimacy regardless of its data — which is why Part I of this course exists.



1967: shaved mice, a ruby laser — and unexpectedly faster hair regrowth.

de Freitas LF, Hamblin MR. IEEE J Sel Top Quantum Electron. 2016;22(3):7000417.

NASA LEDs and the Terminology Shift

- NASA develops LED arrays for plant growth and wound-healing experiments in microgravity.
- Those device families (e.g., WARP-10, GentleWaves) are later repurposed for early ocular pilot studies in AMD — the TORPA series in Part IV.
- Coherence proves unnecessary: inexpensive, safe LED sources reproduce laser biostimulation effects.

Red LED plant-growth arrays (AI-generated)

Naming the field

Low-level laser therapy
laser-era term
↓
Low-level light therapy
admits LEDs
↓
Photobiomodulation (PBM)
current standard — mechanism-based, source-agnostic

de Freitas LF, Hamblin MR. 2016 · Moghbar L, et al. JAAD 2024.

PART II · HISTORY OF LIGHT IN MEDICINE

Dermatology as the Proving Ground for LED Therapy

Band	Wavelengths	Dermatologic effect
Blue	400–470 nm	Porphyrin-mediated antibacterial effect (C. acnes); barrier repair
Yellow	570–595 nm	Melanogenesis suppression; melasma, photoaging
Red	620–700 nm	Collagen synthesis, wound healing, hair growth
Near-infrared	700–1440 nm	Deep repair; pigmentary disorders, accelerated wound healing

- PBM is generally well-tolerated and safe — erythema is the most common cutaneous adverse effect and is self-limiting.
- Combination-wavelength protocols outperforming single wavelengths set the conceptual precedent for multiwavelength ocular PBM.

Maghfour J. et al. J Am Acad Dermatol. 2024;91(3):793-802.

37 / 100

PART III · ANTERIOR SEGMENT: DRY EYE & MGD

Clinical Framing: Evaporative Dry Eye and MGD

- Evaporative dry eye with meibomian gland dysfunction is the dominant subtype in clinic populations.
- Chronic, progressive, and structurally consequential — gland dropout is not recoverable.
- Device-based light therapy targets the drivers, not just the symptoms.

Meibography: dropout & engorgement (our clinic)

Therapeutic targets

- Terminal duct obstruction
- Elevated meibum viscosity
- Lid margin inflammation & telangiectasia
- Demodex colonization
- Ocular rosacea

38 / 100

PART III · ANTERIOR SEGMENT: DRY EYE & MGD

Where Light Therapy Sits: TFOS DEWS III Staged Management

Step 1 · Tear film replenishment & conservation
Lubricants, environmental modification, lid measures

Step 2 · MGD-directed therapy
Warm compresses · device lid warming · IPL · LLLT

Step 3 · Lid hygiene & anti-inflammatory therapy
Topical/systemic anti-inflammatories, biologics

Step 4 · Advanced options
Surgical and specialty interventions

IPL and LLLT sit at Step 2 — after replenishment, alongside gland-directed physical therapy.

Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III Management and Therapy Report. Am J Ophthalmol. 2023.

39 / 100

PART III · ANTERIOR SEGMENT: DRY EYE & MGD

IPL vs. LLLT: Establish the Distinction Early

	Intense Pulsed Light (IPL)	Low-Level Light Therapy (LLLT)
Source	Xenon flashlamp, broadband 500–1200 nm, filtered	LED array, narrow-band (typically 590–633 nm)
Physics	High-energy pulse trains — photothermal / vascular	Low irradiance, continuous — photobiomodulation
Where applied	Periocular skin, eyes shielded	Over closed eyelids
Primary target	Telangiectasia, inflammation, meibum viscosity, Demodex	Cellular metabolism of lid and gland tissue
In practice	*Different physics, different targets — frequently combined in a single session*	

Di Nardo S. et al. Cornea. 2022;41(9):1080-1087.

40 / 100

PART III · ANTERIOR SEGMENT: DRY EYE & MGD

IPL Physics

- **Source** — Xenon flashlamp — broadband, non-coherent, 500–1200 nm
- **Filtering** — Cut-off / notch filters shape the spectrum (e.g., 590 nm "acne" filter blocks shorter wavelengths)
- **Delivery** — Pulse trains with controlled pulse width and intervals
- **Coupling** — Chilled optical gel couples the handpiece and protects the epidermis
- **Safety** — Opaque eye shields are mandatory — always, every pass

Opaque shields, coupling gel, periocular passes (AI-generated illustration)

41 / 100

PART III · ANTERIOR SEGMENT: DRY EYE & MGD

IPL: Proposed Mechanisms in MGD

Vascular
Closure of abnormal telangiectatic lid margin vessels — removing a source of inflammatory mediators

Anti-inflammatory
Reduction of inflammatory cytokines measurable in tears

Thermal
Heating liquefies viscous, inspissated meibum, easing expression

Antiparasitic
Reduction of Demodex burden on the lids

42 / 100

AAO Ophthalmic Technology Assessment: IPL for MGD

12

studies assessed:
4 level II · 8 level III

All 12 documented improvement in clinically meaningful metrics:
tear break-up time · corneal staining · eyelid margin measurements · meibum quality · gland expressibility · OSDI · SPEED

- Side effects were relatively uncommon — discomfort, cutaneous erythema, blistering, eyelash loss, floaters — and uniformly self-limited.
- Five of the twelve studies had potential conflicts of interest and design limitations affecting interpretation — keep that weight in mind as we read the trial data next.

Randomized Evidence: IPL + MGX vs. Sham + MGX



- Design: 1:1 randomization, 4 sessions at 2-week intervals; patients and examiners blinded.
- Primary outcome (TBUT): IPL+MGX 4.0 → 6.0 s vs. sham+MGX 3.8 → 4.5 s — between-arm difference significant (P < .01).
- No serious adverse events in either arm.

Same Trial: Secondary Outcomes — and the Honest Caveats

Favored IPL + MGX

- Meibomian gland score (P < .001)
- Eye Dryness Score (P < .01)
- Expressible gland counts, upper and lower lids (P < .0001)
- Predominant meibum quality, both lids (P < .0001)
- Less pain during expression (P < .0001)

The honest caveats

- OSDI improved in both arms with no between-arm difference (P = .9984) — expression alone relieves symptoms
- Daily artificial tear use: no between-arm difference (P = .8216)
- Meibography (gland structure): no significant change in either arm
- Sponsor-funded; authors consult for the manufacturer

Arita: Level II Data with 32-Week Follow-up

+21.3 nm
lipid layer thickness (max mean increase)

+4.5 s
tear break-up time

−9.2
SPEED symptom score at 32 weeks

−1.9 / 6
eyelid margin score

- Design: 90 eyes of 45 patients; M22 device at 14–16 J/cm²; 8 sessions at 3-week intervals; outcomes through 32 weeks.
- Also improved: meibum grade (−0.3) and corneal staining (−1.0) vs. expression alone.
- Caveats: three patients withdrew because of IPL-associated pain; the first author consulted for the device manufacturer.

What Improvement Looks Like: From Our Chairs

Lid margin — before (L) and after (R) IPL series.



Lid margin & lashes — before (L) and after (R).

Periocular erythema — IPL series.

Honest frame: single cases, not trials — the RCTs you just saw are why we expect this; these are why patients say yes.

Patient photographs: Hazleton Eye Specialists / The Dry Eye Clinic of NEPA — written photography consent on file for all images.

IPL in Practice: A Typical Protocol

1. **Screen** — Fitzpatrick type, medications, lesions, devices
2. **Shield** — Opaque eye protection — mandatory, every pass
3. **Treat** — Fluence titrated to skin type; gel coupling; tragus-to-tragus passes
4. **Express** — Post-treatment meibomian gland expression
5. **Repeat** — 3–4 sessions at 2–4 week intervals; reassess

KEY POINT Expression after IPL is part of the therapy, not an optional add-on — the trial evidence is for the combination.

IPL Safety and Contraindications

Screen before treating

- Fitzpatrick V–VI: heightened caution, adjusted fluence
- Recent tanning or sun exposure
- Photosensitizing medications: isotretinoin, doxycycline, amiodarone, St. John's wort — but hold that thought (next slide)
- Active herpetic disease · pregnancy
- Melanocytic or suspicious lesions in the field
- Gold implants · pacemakers/ICDs per manufacturer labeling

What the assessment found

- Reported side effects are uncommon and self-limited.
- Typical events: transient discomfort, cutaneous erythema; rarely blistering, eyelash loss, floaters.
- No pattern of serious or permanent harm across the 12 assessed studies.

Fitzpatrick typing guides candidacy & settings

The Doxycycline Paradox

What the labels say

- Photosensitizing medications listed as an IPL precaution
- Tetracyclines (doxycycline), isotretinoin, St. John's wort, amiodarone
- Standard advice: hold the drug or defer the light

What the physics says

- Drug phototoxicity action spectra live in the UVA: 320–400 nm
- Filtered IPL emits ≈ 500–1200 nm — the activating wavelengths never leave the handpiece
- Part I rule, again: no absorption, no effect

What the evidence says

- Kerstein 2014 systematic review: zero published adverse cases of laser/IPL + photosensitizers
- Schilling 2019: 36 rosacea patients on doxycycline through IPL/PDL — no photosensitivity events
- Sorg 2007: >500 nm IPL → no thymine dimers (no UV-type DNA damage)

In our clinic: doxycycline and IPL often run together on purpose — synergistic MGD/rosacea control. Know the labeling, document your reasoning, and treat isotretinoin as its own conversation.

Kerdel RL, et al. Lasers Med Sci. 2014;29(4):1449-52 · Schilling LM, et al. Dermatol Surg. 2019;45(12):1601-05 · Sorg O, et al. Arch Dermatol. 2007;143(3):383-84.

LLLT: Parameters and Delivery

Wavelength	590–633 nm LED arrays (device-dependent; some add NIR)
Application	Mask or panel over closed eyelids
Session	Typically ~15 minutes
Sensation	Gentle warmth — often paired with lid warming
Course	Multiple sessions over weeks; maintenance as needed

633 nm LED mask in use — closed lids, low irradiance.

Randomized, Observer-Masked LLLT Trial

Significant vs. placebo

- Fluorescein corneal staining — the primary endpoint
- Lissamine green conjunctival staining
- Schirmer testing
- Upper meibography scores

Improved, not significant

- Tear break-up time
- Lid debris · lid swelling · telangiectasia
- Meibum secretion and expressibility

Design: 6 sessions over 3 weeks, observer-masked, placebo-controlled. No serious adverse events.

Park Y, Kim H, Kim S, Chu KJ. Sci Rep. 2022;12:3375.

Prospective 633 nm LLLT: What Improves — and What Doesn't

+12.9 nm	+0.06 mm	−10.2	+7.0 °C
lipid layer thickness	tear meniscus height	OSDI symptom score	eyelid temperature (upper & lower)

- Also significant: first and average non-invasive break-up time and meibum quality (15 min × 3 visits).

Unchanged: corneal fluorescein staining and meibomian gland dropout. LLLT relieves symptoms and improves tear film function — it does not regenerate lost glands. Set expectations accordingly.

Ashwi A, Schill AW, Rudkin R, Ritchey ER. Ophthalmol Physiol Opt. 2024;44(5):1464-1471.

Head-to-Head: LLLT vs. IPL



- Symptom score: greater improvement with LLLT (−9.9 ± 3.2 vs. −6.75 ± 4.5; P = 0.014).
- Tear meniscus height: increased with LLLT, not IPL (0.06 ± 0.10 mm vs. −0.01 ± 0.014 mm; P = 0.040).
- No significant change in either group: non-invasive break-up time, redness score, meiboscore, gland loss.
- No adverse events in either arm — both modalities tolerated well over 4 weekly sessions.

Giannaccare G, Pellegrini M, Camerelli Scalzo G, et al. Cornea. 2023;42(2):141-144.

Combined IPL + LLLT: Clinical Outcomes in Recalcitrant Disease

95.6%
of eyes: OSDI significantly reduced

72.3%
of eyes: tear break-up time increased

80.8%
of eyes: gland expressibility improved

- Population: 94 eyes with recalcitrant evaporative dry eye disease and MGD — a difficult, pre-treated group.
- Intervention: a single combined IPL + LLLT session (Eye-light device).
- All three outcomes significant at 3 months (P < .05) and sustained at 6 months.

Combined IPL + LLLT: Molecular Correlates

↓ **IL-1β**
pro-inflammatory cytokine

↓ **IL-17F**
Th17-axis cytokine

↓ **MMP-9**
matrix metalloproteinase

↓ **MMP-9 / TIMP-1**
protease-inhibitor balance

↓ **B-cell proportion**
ocular surface immune profile

KEY POINT All reductions statistically significant (P < .05). The tear-film proteome corroborates the clinical response — this is not placebo arithmetic.

Anterior Segment Cases (Interactive — 5 min)

Case 1

- 48-year-old with rosacea and telangiectatic lid margins
- Oxford grade 2 corneal staining

Discussion: build an IPL-anchored plan — filter choice, fluence for skin type, session cadence, expression.

Case 2

- 62-year-old with advanced gland dropout on meibography
- Symptomatic despite lid hygiene and lubricants

Discussion: symptom relief is achievable without structural reversal — frame expectations before the first session, not after the last.

Crosslinking: The Photochemical Quadrant, Realized

The mechanism — a designed chromophore

- Riboflavin 5′-phosphate (vitamin B2) saturates the stroma — an installed photosensitizer
- UVA at 365 nm excites riboflavin → singlet oxygen → covalent crosslinks between collagen fibrils
- Result: a measurably stiffer cornea — progression of ectasia halts
- Oxygen is a reagent: crosslinking consumes O_2 — the chemistry that shaped 2025's new protocol

Every Part I rule, on display

- Grotthuss-Draper: no absorption, no effect — here the absorber is supplied in a bottle, not borrowed from the mitochondria
- Dosimetry: Dresden protocol = 3 mW/cm² × 30 min = 5.4 J/cm²
- Accelerated protocols trade irradiance against time at matched fluence — reciprocity, with limits set by oxygen depletion
- Four-modes grid: this is the photochemical quadrant — PBM's neighbor, not its sibling

Riboflavin fluorescence under UVA (AI-generated illustration)

Contrast to remember: PBM borrows an endogenous chromophore to signal; CXL installs an exogenous one to build. Same physics discipline, opposite quadrant.

CXL Evidence: From Dresden to Epi-On (October 2025)

Epi-off: the established standard

- Dresden protocol (Wollensak 2003) → first US FDA approval April 2016 (Photrexa / KXL)
- Indication: progressive keratoconus and post-refractive corneal ectasia
- Halts progression; the alternative it prevents is corneal transplantation
- A generation of keratoconus patients has already been changed by a light therapy

Epi-on: approved October 20, 2025

- Epioxa HD 0.239% / Epioxa 0.177% — first FDA-approved epithelium-on CXL; ages 13+
- Oxygen-enriched: O_2n system + Boost Goggles feed the O_2-hungry photochemistry
- Two Phase 3 RCTs, 400+ patients — primary endpoint met (≥1.0 D Kmax difference vs sham, 12 mo)
- No epithelial debridement → less pain, faster recovery; commercial early 2026
- Caution: herpetic keratitis history (UV reactivation); aphakia/pseudophakia without UV-blocking IOL

Why it belongs in this lecture: CXL is the proof that a light-driven eye therapy can travel bench → FDA → standard of care. That is the road PBM is on.

The CXL Playbook: What 0402T Teaches Us About 0936T

2016
Approval → coding chaos
Billed on Category III 0402T + unclassified drug code — frequent denials and rejections

2019
Advocacy → J-code
ASCRS-led push wins dedicated J2787 for riboflavin — claims clean up

2026
Tenth year → covered
≈95% of payers cover epi-off — while 0402T is STILL a Category III code

The lessons for retinal PBM — and for your Tuesday-morning claims

- Category III ≠ non-covered: CXL reached ~95% payer coverage without ever earning a Category I code — documentation of progression + preauthorization discipline did the work
- History rhymes in real time: brand-new epi-on is being excluded as "experimental" by major payers today — the same wilderness 0936T is in right now

Bridge to Part IV: one light therapy already ran this whole course, from photochemistry to paid claims. Now: the retina.

PART IV · POSTERIOR SEGMENT: PBM FOR DRY AMD

The Unmet Need in Non-Neovascular AMD

Early / intermediate

AREDS2 supplementation · risk-factor modification · monitoring

THE GAP

No approved therapy modifies progression in early and intermediate disease

Established GA

Complement inhibition for geographic atrophy; anti-VEGF if exudative conversion

- Dry AMD remains a leading cause of irreversible central vision loss in older adults.
- Patients in the gap are told to take vitamins and wait — the population every optometrist manages, and the population the PBM trials enrolled.

Vemulakonda GA, Bailey ST, Kim SJ, et al. AAO Preferred Practice Pattern. Ophthalmology. 2025;132(4):P1-P74.

PART IV · POSTERIOR SEGMENT: PBM FOR DRY AMD

Pathophysiologic Rationale: Why PBM Might Work Here

RPE mitochondrial dysfunction	PBM's primary target is mitochondrial — CCO-mediated bioenergetic restoration
Oxidative stress	PBM upregulates antioxidant enzyme programs
Impaired outer-segment phagocytosis	ATP-dependent RPE housekeeping — energy supply is rate-limiting
Drusen accumulation	Downstream of RPE metabolic failure; the measurable anatomic burden
Chronic parainflammation	PBM's documented anti-inflammatory signaling

de Freitas LF, Hamblin MR. 2016 · Sin G, et al. 2026.

PART IV · POSTERIOR SEGMENT: PBM FOR DRY AMD

Retinal PBM Mechanism

- Cytochrome c oxidase upregulation — demonstrated at 670 nm in photoreceptors, with additional effects documented in RPE and Müller cells.
- Additional reported effects: reduced inflammation, modulated phagocytosis, VEGF downregulation, direct neuroprotection.
- The precise site and mechanism of action remain under active debate — including PBM's placement within the RELITE framework.

Cellular targets

Photoreceptors

highest mitochondrial density in the body

RPE

phagocytosis, transport, drusen biology

Müller cells

metabolic support, inflammation

Boyer D, et al. Retina. 2024;44(3):487-497 · de Freitas & Hamblin 2016 · Siqueira RC. Clin Ophthalmol. 2024;18:213-225.

PART IV · POSTERIOR SEGMENT: PBM FOR DRY AMD

Preclinical Foundations: Why Anyone Believed This

670 nm rescues CCO poisoning	Methanol-derived formate inhibits CCO; three brief 670 nm doses preserved rod/cone ERG and retinal structure in rats — toxin and therapy meet at one enzyme.
670 nm quiets complement	Reduced C3 deposition on Bruch's membrane and photoreceptors in CFH$^{-/-}$ AMD-model mice — the same pathway approved GA drugs target.
NO is reduced in human AMD	eNOS and nNOS immunoreactivity fall in AMD eyes — the mechanistic seat for 590 nm nitric-oxide stimulation.
Multiwavelength: protective, non-toxic	Protected retinal layers in a $NaIO_3$ rat model; no RPE cytotoxicity in culture up to 18 J/cm².

All preclinical — animal models and cell culture. Presented as rationale, not as clinical evidence.

Sohn JT, et al. Proc Natl Acad Sci USA. 2003;100:3429-3444 · Begum R, et al. PLoS One. 2013;8:e57828 · Bhutto IA, et al. Exp Eye Res. 2010;90:153-167 · Gao H, et al. Int J Mol Sci. 2023;24.

PART IV · POSTERIOR SEGMENT: PBM FOR DRY AMD

Why Multiwavelength?

590 nm

delivered open eye

stimulates nitric oxide synthesis and vasodilation — improved local oxygenation and nutrient delivery

660 nm

delivered closed lid

promotes O_2 binding at the Cu_B center — stimulates ATP; inhibits inflammation and cell death

850 nm

delivered open eye

drives electron transfer at the Cu_A center — stimulates ATP; deepest penetration to photoreceptors and RPE

KEY POINT Three wavelengths, two delivery routes, complementary chromophores and depths — the multiwavelength logic from dermatology, applied to the retina.

Wong-Riley MTT, et al. J Biol Chem. 2005;280:4761-4771 · Ball KA, et al. J Photochem Photobiol B. 2012;102:182-191 · Boyer D, et al. Retina. 2024.

PART IV · POSTERIOR SEGMENT: PBM FOR DRY AMD

Pilot Work: TORPA I and II

- Interventional case series using off-label NASA-lineage devices (WARP-10, GentleWaves).
- Protocol: 590, 670, 790 nm; pulsed 2.5 Hz; 0.1 J/cm² per treatment; three times weekly for six weeks.
- TORPA II at 3 months: mean BCVA +5.14 ETDRS letters ($P < .001$), contrast sensitivity gain, reduced drusen volume and central thickness — without new geographic atrophy.
- Effect declined after roughly 4 months — establishing the rationale for periodic re-treatment that every later trial adopted.

+5.14

ETDRS letters at 3 months (TORPA II)

Pilot-grade evidence: uncontrolled case series — hypothesis-generating, not practice-changing on its own.

Merry GF, et al. Acta Ophthalmol. 2017;95(4):e270-e277.

The Negative Evidence: LIGHTSITE I / II and Cochrane

LIGHTSITE I, LIGHTSITE II, and the 2021 Cochrane systematic review did not show a benefit of photobiomodulation for non-exudative AMD.

- Early trials were small, endpoints varied, and effects did not reach significance.
- The Cochrane conclusion (2021): evidence insufficient to demonstrate benefit.
- Everything you are about to see must be weighed against this starting point — not presented in isolation from it.

Herron C, Steel DH. Cochrane Database Syst Rev. 2021;9:CD013029 · Venugalondo GA, et al. AAO PPP. Ophthalmology. 2025.

LIGHTSITE III: Design

Design	Double-masked · randomized · sham-controlled · parallel-group · multicenter · prospective
Population	100 subjects / 148 eyes with dry (non-neovascular) AMD
Intervention	Multiwavelength PBM: 590, 660, 850 nm — 2:1 randomization vs. sham
Sham	Not optically empty: 10×/100×-reduced 590 and 660 nm; 850 nm removed
Schedule	9 treatments over 3–5 weeks, repeated every 4 months, through 24 months

Each dot = a 9-session series delivered over 3–5 weeks

Boyer D, Hu A, Warrow D, et al. Retina. 2024;44(3):487-497.

LIGHTSITE III: 13-Month BCVA — Primary Endpoint Met



- Primary BCVA endpoint met: between-group difference 2.4 letters (SE 1.15; P = 0.02).
- PBM arm: +5.4 letters (95% CI 3.5–7.3; P < .0001 within group). Sham arm: +3.0 letters.

Why did sham eyes gain 3 letters? Repeat ETDRS testing effects — and the sham was not optically empty (low-dose 590/660 nm). A conservative comparator that, if anything, understates the treatment effect.

Boyer D, et al. Retina. 2024;44(3):487-497.

LIGHTSITE III: 13-Month Anatomic Outcome

OR 9.4

odds ratio for new-onset GA, sham vs. PBM (P = 0.024)

- Significant decrease in new-onset geographic atrophy in the PBM group (Fisher exact test, P = 0.024).
- Favorable safety profile through 13 months — no phototoxicity signal.

Why it matters: letters fluctuate; conversion to GA is the disease milestone patients fear. An anatomic progression signal is the stronger claim — and the one to scrutinize hardest.

Boyer D, et al. Retina. 2024;44(3):487-497.

LIGHTSITE III: 24-Month BCVA and Responder Analysis



- Prespecified primary BCVA endpoint met at month 21 (P = 0.0036).
- Mean gain after PBM: +6.2 letters.
- Majority of treated eyes (61.5%) gained a line or more; a quarter gained two lines.

Post-hoc Cox model: hazard ratio 0.47 for >5-letter BCVA loss over 24 months (P < 0.02) — a 53% reduction in onset of vision loss.

Jaffe GJ, et al. Retina. 2024;44(5):783-793 · Do D, et al. Presented at AAO, Chicago, Oct 2024 (post-hoc).

LIGHTSITE III: 24-Month Disease Progression and Safety



- Progression to geographic atrophy by month 24: 6.8% with PBM vs. 24.0% with sham (P = 0.007).
- Favorable safety profile with no signs of phototoxicity through 24 months.
- Significant benefit in vision-related quality of life.

Post-hoc Cox model: hazard ratio 0.27 for incident GA (P < 0.006) — a 73% risk reduction. Headline claims; the AAO evidence grade two slides ahead asks you to hold them loosely.

Jaffe GJ, et al. Retina. 2024;44(5):783-793 · Do D, et al. Presented at AAO, Chicago, Oct 2024 (post-hoc).

Independent Confirmation: 12-Month Multicentre RCT



- 138 eyes of 78 patients with early or intermediate dry AMD; double-masked, sham-controlled, multicentre.
- Primary outcome: drusen volume fell with PBM (−0.03 ± 0.05 mm^3) and rose with sham (+0.02 ± 0.04 mm^3); P < .001.
- BCVA: +1.31 letters PBM vs. −2.62 sham — between-group +3.75 letters (95% CI 1.16–6.34; P = .0001).
- Macular neovascularisation: 4 sham eyes vs. 0 PBM eyes (P = .044). Independent of the device sponsor's trial program.

Irvine C, Borrelli E, Cozzi G, et al. Br J Ophthalmol. 2024 (online first).

One Patient, 24 Months

LIGHTSITE III: Macular Drusen Volume Reduction

Visit 1, Screening Visit

Visit 60, Month 21 Visit (After 6 series of PBM)



Representative OCT imaging from a 77-year-old female subject showing a significant reduction in macular drusen volume after the final series of PBM treatment at Month 21 without visible loss of photoreceptor or retinal pigment epithelium.

Starting BCVA: 75 letters

Month 13 BCVA (4 series of PBM): 79 letters; 4 letter gain

Month 21 BCVA (6 series of PBM): 84 letters; 9 letter gain

Month 24 BCVA (3 months after final PBM Tx): 82 letters; 7 letter gain

The story

- 77-year-old female, dry AMD
- Screening BCVA: 75 letters
- Month 21 (6 series): 84 letters — +9
- Drusen volume visibly reduced on OCT
- No photoreceptor or RPE loss beneath
- This is what "disease modification" looks like on your own OCT

Boyer D, et al. Retina. 2024;44(3):487-497 — representative subject; imaging courtesy LumiThera slide library (used with permission).

Regulatory and Guideline Status: Hold Both at Once

FDA · 2024

Approved the Valeda Light Delivery System for multiwavelength photobiomodulation treatment of patients with non-neovascular AMD — the first interventional authorization in this population.

AAO PPP · 2025

Notes LIGHTSITE I/II and the 2021 Cochrane review did not show benefit, while LIGHTSITE III showed decreased onset of new GA (P = 0.02) — and grades the evidence:

"I–, insufficient quality"

Both statements are true simultaneously. Regulatory authorization is not an evidence grade — and an evidence grade is not a prohibition.

Vonnudikonda GA, Bailey ST, Kim SJ, et al. AAO Preferred Practice Pattern. Ophthalmology. 2025;132(4):P1-P76.

Cleared vs. Approved vs. Authorized

CLEARED · 510(k)

- Most Class II (moderate-risk) devices
- Standard: "substantially equivalent" to an existing predicate device
- Typically NO new efficacy trial required
- Eye examples: SLT lasers (Selecta II, Tango Reflex), micropulse lasers (IQ 532, MicroPulse P3), LLLT pain devices

APPROVED · PMA / NDA

- Class III (high-risk) devices — and ALL drugs
- Standard: clinical trial data reviewed for safety AND efficacy
- The most stringent pathway
- Examples: pacemakers, cochlear implants; drugs — anti-VEGF agents, Photrexa, Epioxa

AUTHORIZED · De Novo

- Novel low/moderate-risk device with NO predicate to point to
- Clinical data reviewed; grant CREATES a new device classification
- Future devices may cite it as their predicate
- Valeda: authorized November 4, 2024 (DEN230083) — on the strength of LIGHTSITE III

The patient script: "Not cleared like a laser, not approved like a drug — a first-of-its-kind authorization, with the trial we just walked through behind it."

FDA. 510(k), PMA, and De Novo program descriptions. · FDA De Novo DEN230083 (Valeda). Nov. 4, 2024.

Read the Label: Authorization Is Narrower Than the Trial

Labeled indication

- BCVA 20/32 through 20/70 — narrower than the trial's 20/100 floor
- ≥3 medium drusen (>63–≤125 µm), or large drusen (>125 µm), or non-central GA
- No neovascular maculopathy; no center-involving GA

Label's own claim: ~1 line of ETDRS acuity vs. no treatment at ~2 years.

Contraindications & precautions

- Known photosensitivity to yellow, red, or near-infrared light
- History of light-activated CNS disorders (e.g., epilepsy, migraine)
- No treatment within 30 days of photosensitizing agents affected by 590/660/850 nm, absent physician consultation
- Benefit may not persist after stopping; no data beyond 54 treatments per eye

Prescribe to the label; counsel to the trial; monitor to both.

FDA De Novo DEN230083, Valeda Light Delivery System Indications for Use / Important Product Information.

Patient Selection: Mirror the Trial Population

- ✓ Intermediate non-neovascular AMD
- ✓ BCVA 20/32–20/100 in the trial; 20/32–20/70 on the label
- ✓ No center-involving geographic atrophy
- ✓ No active or prior exudative disease in the treated eye
- ✗ Established center-involving GA → complement-inhibition discussion instead
- ✗ Exudative conversion at any point → anti-VEGF pathway, not PBM

KEY POINT Selection discipline is the ethical core of offering this therapy — the data exist only for the enrolled phenotype.

Boyer D, et al. Retina. 2024 · Jaffe GJ, et al. Retina. 2026.

The Device in the Room

What staff see

- Tabletop unit — slit-lamp posture, chin rest
- Touchscreen walks the 4 phases
- Live view of the treated eye
- ≈ 4 min per eye; no dilation
- 590 / 660 / 850 nm LEDs — the three dots on every slide today

Valeda Light Delivery System (LumiThera → Alcon). Photos: LumiThera clinical library, used with permission.

Treatment Protocol in Practice

Series	9 sessions over 3–5 weeks — three per week is the preferred cadence
Re-treatment	Repeat the full series approximately every 4 months — benefit wanes without it
Delivery	590 + 850 nm pulsed (open eye); 660 nm continuous (closed lid) — alternating phases
Dose	Device outputs 5 / 65 / 8 mW/cm² at 590 / 660 / 850 nm; 250 s per eye; no dilation
Chair time	About 4 minutes per eye — delegable after training

Jaffe GJ, et al. Retina. 2024 · Device outputs: manufacturer specifications (Valeda User Manual).

Workup and Monitoring: Match the Trial Endpoints

BCVA (ETDRS if available)	the functional primary endpoint
Contrast sensitivity	often moves before acuity
OCT with drusen volume analysis	the anatomic endpoint that changed in both RCT programs
Fundus autofluorescence	geographic atrophy mapping — the progression milestone
OCT-A where available	surveillance for neovascular conversion

KEY POINT If you cannot measure the trial endpoints, you cannot verify the trial benefit in your patient.

Arepalli S, et al. BJO 2024 · Jaffe GJ, et al. Retina 2024.

Patient Counseling: The Five Sentences

1. *"This is a maintenance therapy, not a cure — the benefit fades if we stop the every-four-month series."*
2. *"It does not replace your AREDS2 vitamins, smoking cessation, or monitoring."*
3. *"If your AMD ever converts to the wet form, anti-VEGF injections take priority — this does not substitute."*
4. *"In the pivotal trial, treated eyes gained about six letters by two years — and untreated eyes also improved somewhat, so the added benefit is real but modest."*
5. *"The strongest signal is fewer eyes progressing to atrophy — about 7% versus 24% at two years."*

Boyer D, et al. Retina. 2024;44(3):487-497.

Practice Logistics

Chair time
Short sessions, but 9 visits × 3 series/year per patient — model the schedule before buying

Staffing
IPL/LLLT delegable per state law — but retinal PBM must be personally performed by an OD/MD/QHP (MAC guidance, next slides)

Scheduling
Recurring 4-month series blocks; recall systems matter more than the device

Reimbursement
CPT 0936T live since Jan 2025; MAC-priced claim-by-claim — ABN workflow + transparent self-pay backstop (next slides)

Follow the Money I: CPT 0936T Arrives

The code
0936T — "Photobiomodulation therapy of retina, single session" · effective Jan 1, 2025 · session = one day · bilateral: modifier -50 per CPT

The payment
No national fee schedule amount — each MAC prices claim-by-claim; varies by region & payer. 2025 experience: many claims paid

The coverage
No LCDs yet; ≥ 1 national commercial policy lists 0936T non-covered → ABN on every Medicare patient; self-pay backstop

The provider
Personally performed by OD / MD / QHP — MAC medical directors (Mar 2025): NOT MAs or techs, even supervised. Incident-to 100% vs 85%

Diagnosis coding: ICD-10 H35.31- (nonexudative AMD) · 6th digit = eye · 7th digit: 1 early, 2 intermediate — on-label = intermediate.

Corcoran KJ. Retinal Physician. Nov/Dec 2025 · AMA CPT 2025 · CMS MPFS CY2025.

Straight From the Biller's Mouth: 0936T in NEPA

Paying

- **Medicare:** $272.55 allowable per session; $45.44 coinsurance to patient or secondary
- **Humana MA:** $228 paid; patient $40 copay
- **UnitedHealthcare:** $121.26 per eye; patient $35 copay

Secondaries covering the 20%

- HOP
- AARP
- Some Blue Cross plans
- GHI — leaves a $15 copay
- Some Aetna plans
- Mutual of Omaha
- Bankers

Denies — no matter what

- Tricare
- Medical Assistance (Medicaid)
- Veterans Assistance
- Geisinger

The workflow this dictates: verify plan-by-plan BEFORE session one, ABN every Medicare patient, and collect the known copay at check-in — not after nine visits.

Source: our billing team — adjudicated claims, our practice, Norristown jurisdiction (PA), as of Sept 2026. Regional experience; your MAC and plan mix will differ.

The Napkin Version

MONEY IN	≈ $2,450	one Medicare patient course: 9 sessions × $272.55
MONEY OUT	− $270–450	consumable cost for that course (volume tier)
WHAT STAYS	≈ $2,000–2,180	gross margin per completed course
THE BOX	$75–90K → ≈ 35–45 courses	device cost ÷ what stays = break-even

One sentence: a Medicare course nets about two grand — and the machine costs about forty of those. The real constraint is doctor minutes, because 0936T must be personally performed.

Arithmetic from our Medicare experience ($272.55/session, 9-session course) and vendor consumable here ($270–450/course). Illustrative; excludes staff time, financing, and rent.

Follow the Money II: Unit Economics (Illustrative)

Disclaimer: educational arithmetic only — not pricing guidance, not fee coordination. Inputs are public/vendor estimates or hypothetical. Every practice sets its own fees independently.

The cost stack

- Device capital: ≈ $75–90K (market estimate)
- Per-treatment fee (tiered by volume): ≈ $50 → $30 ($450 → $270 per 9-treatment course)
- On-label year: 3 series × 9 = 27 treatments → consumables ≈ $810–$1,350 / treated year
- Confirm with vendor: per EYE or per PATIENT — and terms continue to change

Device payback — illustrative

Courses to recover capital = capital ÷ [9 × (net revenue/session − click fee)]

Net $/session (hypothetical)	Courses to break even	≈ Patient-years
$150	≈ 70–100	≈ 23–33
$250	≈ 38–50	≈ 13–17

(Uses click fee $50 → $30 across volume tiers; 3 courses ≈ 1 patient-year)

The real cost line: doctor minutes. PBM is personally performed — every session competes with exam-lane revenue. IPL delegation math does not transfer.

Device cost & per-treatment fees: market estimates, subject to change · Concerto Rx Retinal Physician, 2025.

Investigational Frontiers — Every Item Off-Label

Diabetic macular edema
Case-level reduction in central retinal thickness and hard exudates

Central serous chorioretinopathy
Case-level subretinal fluid resolution, maintained at ~1 year

Reticular pseudodrusen
SD-OCT stage regression at 6 months in case series

Retinitis pigmentosa
Early pilot investigation only

Evidence tier: case reports and pilot series only — hypothesis-generating, not practice-changing. All uses off-label. (Glaucoma: next slide.)

Kiymak H, et al. Clin Ophthalmol. 2023 · Sachdev A, et al. Ophthalmol Ther. 2024 · Le MH, et al. Medicine (Kaunas). 2022 · Siqueira RC. Clin Ophthalmol. 2024.

Frontiers, Illustrated I: DME & Central Serous





Same rules as the last slide: case-level imaging, off-label — this shows biological plausibility, not efficacy. But it is why the trials are being run.

Kiymak H, et al. Clin Ophthalmol. 2023 · Sachdev A, et al. Ophthalmol Ther. 2024 — imaging via LumiThera library (used with permission).

Frontiers, Illustrated II: RPD & Drusenoid PED





Pattern to notice: across four different lesion types, the imaging moves the same direction — structures regress without atrophy underneath. Mechanism-consistent, trial-unproven.

Le MH, et al. Medicine (Kaunas). 2022 · Bertelsbi M, et al. Retina. 2023 — imaging via LumiThera library (used with permission).

Glaucoma: Compelling Biology, Zero Human Trials

Why it SHOULD work

- RGCs: among the most mitochondria-dense neurons in the body
- Glaucoma has a recognized bioenergetic component beyond IOP
- CCO-targeted therapy meets an energy-failure disease — the AMD logic, one synapse upstream

Preclinical signal

- Red light attenuated RGC death in culture and in situ (2016)
- Optic nerve crush, 660/830 nm: PhNR amplitude ≈ +39% vs untreated (ARVO 2025)
- Rat NAION, 670 nm: ≈ 1.6× RGC survival; > 3× FVEP amplitude; apoptosis ↓
- OHT models: RGC & optic-nerve architecture preserved; Bcl-2 ↑, Bax / caspase-9 ↓

Human evidence

- No adequate randomized trials
- Only tiny non-randomized series
- PBM does not lower IOP — adjunctive neuroprotection at best
- Nothing practice-relevant today

Evidence tier: preclinical only — a rung BELOW the case reports on the previous slide. This is AMD at the TORPA stage: on the disclosure slide, off the treatment plan.

Counterpoint: Red Light Is Not Inherently Benign

Documented harms with repeated red-light exposure (myopia-control context, off-label)

- 12-year-old: foveal injury and macular hypoautofluorescence after repeated red laser therapy — bilateral ellipsoid-zone disruption on OCT; only partial visual recovery after cessation
- Separate report: reduced cone photoreceptor density after 1 year of treatment
- One study: structural OCT changes in 7% of children after 1–6 months of treatment

[Insert licensed OCT figure: bilateral EZ disruption at the fovea, partial recovery 3 months after discontinuation — Liu et al., Figure 2]

Device bench testing has also found some consumer units exceeding assumed exposure classes (Ostrin & Schill 2026).

...But the Larger Datasets Are Reassuring



- 246-child multicenter RCT: no severe adverse events, no functional visual loss, no structural OCT damage at 12 months.
- Double-masked, sham-controlled RCT: no treatment-related adverse events.
- 336-child randomized trial: masked fundus photograph review identified no retinal changes in either group.

Resolution: the tension is unresolved — device characteristics and dosimetry, not the color of the light, determine safety.

Key Takeaways

1. **Physics governs everything** — Wavelength selects the chromophore; dose determines the direction of effect — the biphasic response is the master rule.
2. **Anterior segment** — IPL and LLLT both carry randomized support in MGD, are frequently synergistic, and improve symptoms and function — without reversing gland dropout.
3. **Posterior segment** — Multiwavelength PBM is the first FDA-authorized interventional option for non-neovascular AMD — positive 24-month randomized and independent 12-month data, tempered by an AAO evidence grade of I–, insufficient quality.
4. **The field's unmet need** — Standardization of parameters — without it, every device comparison and every meta-analysis stays muddy.

Questions & Discussion

James Deom, OD, MPH, FAAO, FSLS · [email] · Hazleton Eye Specialists

Full reference list available on request — and appended to this deck.

References (1 of 5) — Mechanism, Dosimetry, History

1. Shi G, Wei K, Wang R, et al. Mechanisms of action and clinical research progress of photobiomodulation. J Photochem Photobiol B. 2026;282:113529.
2. Tsai SR, Hamblin MR. Biological effects and medical applications of infrared radiation. J Photochem Photobiol B. 2017;170:197-207.
3. Hamblin MR. Photobiomodulation for traumatic brain injury and stroke. J Neurosci Res. 2018;96(4):731-743.
4. Maghfour J, Ozog DM, Mineroff J, et al. Photobiomodulation CME Part I: overview and mechanism of action. J Am Acad Dermatol. 2024;91(5):793-802.
5. von der Burchard C, Miura Y, Stanzel B, et al. Regenerative Retinal Laser and Light Therapies (RELITE): proposal of a new nomenclature, categorization, and trial reporting standard. Lasers Surg Med. 2024;56(8):693-708.
6. de Freitas LF, Hamblin MR. Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE J Sel Top Quantum Electron. 2016;22(3):7000417.
7. Rojas JC, Gonzalez-Lima F. Low-level light therapy of the eye and brain. Eye Brain. 2011;3:49-67.
8. Jarrett P, Scragg R. A short history of phototherapy, vitamin D and skin disease. Photochem Photobiol Sci. 2017;16(3):283-290.
9. Hönigsmann H. History of phototherapy in dermatology. Photochem Photobiol Sci. 2013;12(1):16-21.
10. Grzybowski A, Sak J, Pawlikowski J. A brief report on the history of phototherapy. Clin Dermatol. 2016;34(5):532-537.
11. Bouceiro Mendes R, Alpalhão M, Filipe P. UVB phototherapy in the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2022;38(3):215-223.
12. Cremer RJ, Perryman PW, Richards DH. Influence of light on the hyperbilirubinaemia of infants. Lancet. 1958;1(7030):1094-1097.
13. Lucey J, Ferreiro M, Hewitt J. Prevention of hyperbilirubinemia of prematurity by phototherapy. Pediatrics. 1968;41(6):1047-1054.

APPENDIX

References (2 of 5) — Anterior Segment & TORPA

14. Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III Management and Therapy Report. Am J Ophthalmol. 2025.

15. Toyos R, Desai NR, Toyos M, Dell SJ. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: a randomized controlled study. PLoS One. 2022;17(6):e0270268.

16. Wladis EJ, Aakalu VK, Foster JA, et al. Intense pulsed light for meibomian gland disease: a report by the American Academy of Ophthalmology. Ophthalmology. 2020;127(9):1227-1233.

17. Park Y, Kim H, Kim S, Cho KJ. Effect of low-level light therapy in patients with dry eye: a prospective, randomized, observer-masked trial. Sci Rep. 2022;12:3575.

18. Antwi A, Schill AW, Redfern R, Ritchey ER. Effect of low-level light therapy in individuals with dry eye disease. Ophthalmic Physiol Opt. 2024;44(7):1464-1471.

19. Giannaccare G, Pellegrini M, Carnovale Scalzo G, et al. Low-level light therapy versus intense pulsed light for the treatment of meibomian gland dysfunction. Cornea. 2023;42(2):141-144.

20. D'Souza S, Padmanabhan Nair A, Iyappan G, et al. Clinical and molecular outcomes after combined intense pulsed light therapy with low-level light therapy in recalcitrant evaporative dry eye disease with meibomian gland dysfunction. Cornea. 2022;41(9):1080-1087.

21. D'Souza S, James E, Koul A, et al. A randomized controlled study evaluating outcomes of intense pulsed light and low-level light therapy for treating meibomian gland dysfunction and evaporative dry eye. Indian J Ophthalmol. 2023;71(4):1608-1612.

22. Merry GF, Munk MR, Dotson RS, Walker MG, Devenyi RG. Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration. Acta Ophthalmol. 2017;95(4):e270-e277.

APPENDIX

References (3 of 5) — Posterior Segment, Guidelines, Safety

23. Boyer D, Hu A, Warrow D, et al. LIGHTSITE III: 13-month efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative (dry) age-related macular degeneration using the LumiThera Valeda Light Delivery System. Retina. 2024;44(3):487-497.

24. Jaffe GJ, Boyer D, Hu A, et al. Long-term efficacy and safety of photobiomodulation in dry age-related macular degeneration (LIGHTSITE III: 24-month analysis). Retina. 2026;46(5):783-795.

25. Iovino C, Borrelli E, Coco G, et al. 12-month outcomes of photobiomodulation in dry age-related macular degeneration: a prospective multicentre randomised double-masked controlled clinical trial. Br J Ophthalmol. 2026 (online first).

26. Henein C, Steel DH. Photobiomodulation for non-exudative age-related macular degeneration. Cochrane Database Syst Rev. 2021;5:CD013029.

27. Vemulakonda GA, Bailey ST, Kim SJ, et al. Age-Related Macular Degeneration Preferred Practice Pattern. Ophthalmology. 2025;132(4):P1-P74.

28. Siqueira RC. Photobiomodulation using light-emitting diode (LED) for treatment of retinal diseases. Clin Ophthalmol. 2024;18:215-225.

29. Liu H, Yang Y, Guo J, Peng J, Zhao P. Retinal damage after repeated low-level red-light laser exposure. JAMA Ophthalmol. 2023;141(7):693-695.

30. Ostrin LA, Schill AW. Safety evaluation of 4 red light therapy devices for myopia. JAMA Ophthalmol. 2026.

31. Jiang Y, Zhu Z, Tan X, et al. Effect of repeated low-level red-light therapy for myopia control in children: a multicenter randomized controlled trial. Ophthalmology. 2022;129(5):509-519.

32. Dong J, Zhu Z, Xu H, He M. Myopia control effect of repeated low-level red-light therapy in Chinese children: a randomized, double-blind, controlled clinical trial. Ophthalmology. 2023;130(2):198-204.

33. Cao K, Tian L, Ma DL, et al. Daily low-level red light for spherical equivalent error and axial length in children with myopia. JAMA Ophthalmol. 2024;142(6):560-567.

APPENDIX

References (4 of 5) — Preclinical, Post-Hoc, Labeling, Frontiers

34. Wong-Riley MTT, Liang HL, Eells JT, et al. Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. J Biol Chem. 2005;280:4761-4771.

35. Ball KA, Castello PR, Poyton RO. Low intensity light stimulates nitrite-dependent nitric oxide synthesis but not oxygen consumption by cytochrome c oxidase: implications for phototherapy. J Photochem Photobiol B. 2012;102:182-191.

36. Whelan HT, Desmet K, Buchmann E, et al. Harnessing the cell's own ability to repair and prevent neurodegenerative disease. SPIE Newsroom. 2008.

37. Eells JT, Henry MM, Summerfelt P, et al. Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc Natl Acad Sci USA. 2003;100:3439-3444.

38. Begum R, Powner MB, Hudson N, Hogg C, Jeffery G. Treatment with 670 nm light up regulates cytochrome c oxidase expression and reduces inflammation in an age-related macular degeneration model. PLoS One. 2013;8:e57828.

39. Bhutto IA, Baba T, Merges C, McLeod DS, Lutty GA. Low nitric oxide synthases (NOSs) in eyes with age-related macular degeneration (AMD). Exp Eye Res. 2010;90:155-167.

40. Goo H, Mo S, Park HJ, et al. Multi-wavelength photobiomodulation ameliorates sodium iodate-induced age-related macular degeneration in rats. Int J Mol Sci. 2023;24:17394.

41. Do D, et al. Photobiomodulation for dry AMD (LIGHTSITE III post-hoc analyses). Presented at the American Academy of Ophthalmology, Chicago, IL. October 20, 2024.

42. US Food and Drug Administration. De Novo classification request DEN230083: Valeda Light Delivery System. 2024. And: Valeda Light Delivery System Indications for Use / Important Product Information.

43. Kaymak H, et al. Photobiomodulation in diabetic macular edema. Clin Ophthalmol. 2023.

44. Sachdev A, et al. Photobiomodulation in central serous chorioretinopathy. Ophthalmol Ther. 2024.

45. Le HM, et al. Regression of reticular pseudodrusen following photobiomodulation. Medicina (Kaunas). 2022.

46. Benlahbib M, Cohen SY, Torrell N, et al. Photobiomodulation therapy for large soft drusen and drusenoid pigment epithelial detachment in age-related macular degeneration. Retina. 2023;43:1462-1472.

APPENDIX

References (5 of 5) — Glaucoma Preclinical & Practice Economics

47. Corcoran KJ. Practice management for photobiomodulation of the retina. Retinal Physician. 2025;22(Nov/Dec).

48. American Medical Association. CPT 2025: Category III code 0936T, photobiomodulation therapy of retina, single session (effective January 1, 2025).

49. Del Olmo-Aguado S, Núñez-Álvarez C, Osborne NN. Red light of the visual spectrum attenuates cell death in culture and retinal ganglion cell death in situ. Acta Ophthalmol. 2016;94:e481-e491.

50. Multi-wavelength photobiomodulation mitigates retinal ganglion cell degeneration (optic nerve crush model). Invest Ophthalmol Vis Sci. 2025;66 (ARVO annual meeting abstract).

51. Roles of 670 nm photobiomodulation in a rat model of anterior ischemic optic neuropathy: RGC survival, mitochondrial function, and anti-inflammatory response. 2025 (preclinical report).

52. Chun JM, Choy S, Seok J-W, Kim J-D, Park S-R. Photobiomodulation in animal models of ophthalmic disease: protocol for systematic review and meta-analysis. Front Med. 2026;13:1904150.

53. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003;135:620-627.

54. US FDA. Photrexa / Photrexa Viscous with the KXL System: approval for corneal collagen cross-linking (epithelium-off). April 2016.

55. Glaukos Corp. FDA approval of Epioxa HD 0.239% / Epioxa 0.177% for epithelium-on corneal collagen cross-linking. October 20, 2025.

56. ASCRS. Cross-linking billing guidelines (0402T, J2787); AAO CXL coding fact sheet 2023; Ophthalmology Management 2026 tenth-year reimbursement review.